J Sieper

Summary

Affiliation: Humboldt University
Country: Germany

Publications

  1. ncbi Developments in therapies for spondyloarthritis
    Joachim Sieper
    Rheumatology, Department of Medicine, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Nat Rev Rheumatol 8:280-7. 2012
  2. ncbi Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
    Joachim Sieper
    Correspondence to Joachim Sieper, University Clinic Benjamin Franklin, Medical Department I, Rheumatology, PO Box, Berlin 12200, Germany
    Ann Rheum Dis 71:700-6. 2012
  3. ncbi Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D 12200 Berlin, Germany
    Arthritis Res Ther 13:R95. 2011
  4. ncbi Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Arthritis Res Ther 10:R125. 2008
  5. ncbi The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
    Rieke Alten
    Department of Internal Medicine II, Rheumatology, Schlosspark Klinik Teaching Hospital Charité University Medicine Berlin, Heubnerweg, D 14059 Berlin, Germany
    Arthritis Res Ther 10:R67. 2008
  6. ncbi Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis
    Heiner Appel
    Charite Berlin, Campus Benjamin Franklin, Department for Gastroenterology, Infectiology and Rheumatology, Berlin, Germany
    Arthritis Res Ther 6:R521-34. 2004
  7. ncbi The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Landgrafenstr, 15, 44652 Herne, Germany
    Arthritis Res Ther 10:R104. 2008
  8. ncbi Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis
    Heiner Appel
    , Campus Benjamin Franklin, Department of Gastroenterology, Infectiology and Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    Arthritis Res Ther 8:R143. 2006
  9. ncbi Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
    Désirée M van der Heijde
    Department of Rheumatology, Leiden University Medical Center, Leiden, Leiden, The Netherlands
    Arthritis Res Ther 11:R124. 2009
  10. ncbi How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    J Sieper
    Medical Department, Rheumatology, Campus Benjamin Franklin, Charite, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 64:iv61-4. 2005

Collaborators

Detail Information

Publications135 found, 100 shown here

  1. ncbi Developments in therapies for spondyloarthritis
    Joachim Sieper
    Rheumatology, Department of Medicine, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Nat Rev Rheumatol 8:280-7. 2012
    ..New classification criteria for peripheral SpA will also allow treatment trials to be conducted more systematically than has previously been possible in this subgroup of patients...
  2. ncbi Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
    Joachim Sieper
    Correspondence to Joachim Sieper, University Clinic Benjamin Franklin, Medical Department I, Rheumatology, PO Box, Berlin 12200, Germany
    Ann Rheum Dis 71:700-6. 2012
    ..To describe the efficacy and safety through 5 years of adalimumab treatment in patients with ankylosing spondylitis (AS), and to identify predictors of remission...
  3. ncbi Analysis of IL-17(+) cells in facet joints of patients with spondyloarthritis suggests that the innate immune pathway might be of greater relevance than the Th17-mediated adaptive immune response
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, D 12200 Berlin, Germany
    Arthritis Res Ther 13:R95. 2011
    ....
  4. ncbi Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Arthritis Res Ther 10:R125. 2008
    ..Therefore, we analysed parameters of cartilage degradation, neoangiogenesis, and new bone formation in different cohorts of patients with axial spondyloarthritis with and without treatment with TNF-alpha blocker agents...
  5. ncbi The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis
    Rieke Alten
    Department of Internal Medicine II, Rheumatology, Schlosspark Klinik Teaching Hospital Charité University Medicine Berlin, Heubnerweg, D 14059 Berlin, Germany
    Arthritis Res Ther 10:R67. 2008
    ..IL-1beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production...
  6. ncbi Use of HLA-B27 tetramers to identify low-frequency antigen-specific T cells in Chlamydia-triggered reactive arthritis
    Heiner Appel
    Charite Berlin, Campus Benjamin Franklin, Department for Gastroenterology, Infectiology and Rheumatology, Berlin, Germany
    Arthritis Res Ther 6:R521-34. 2004
    ..These cells can be expanded ex vivo, suggesting that they are immunologically functional...
  7. ncbi The relationship between inflammation and new bone formation in patients with ankylosing spondylitis
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet Herne, Ruhr University Bochum, Landgrafenstr, 15, 44652 Herne, Germany
    Arthritis Res Ther 10:R104. 2008
    ..Whether and how spondylitis and syndesmophyte formation are linked are unclear. Our objective was to investigate whether and how spinal inflammation are associated with new bone formation in ankylosing spondylitis...
  8. ncbi Correlation of histopathological findings and magnetic resonance imaging in the spine of patients with ankylosing spondylitis
    Heiner Appel
    , Campus Benjamin Franklin, Department of Gastroenterology, Infectiology and Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    Arthritis Res Ther 8:R143. 2006
    ..This first study correlating histopathological changes in the spine of patients with AS with findings in MRI scans suggests that a substantial degree of bone marrow inflammation and edema is necessary to be detected by MRI...
  9. ncbi Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis
    Désirée M van der Heijde
    Department of Rheumatology, Leiden University Medical Center, Leiden, Leiden, The Netherlands
    Arthritis Res Ther 11:R124. 2009
    ..We evaluated the three-year impact of adalimumab on patient-reported physical function and health-related quality-of-life (HRQOL) outcomes in patients with active ankylosing spondylitis (AS)...
  10. ncbi How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    J Sieper
    Medical Department, Rheumatology, Campus Benjamin Franklin, Charite, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 64:iv61-4. 2005
    ....
  11. ncbi Critical appraisal of assessment of structural damage in ankylosing spondylitis: implications for treatment outcomes
    Joachim Sieper
    , Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 58:649-56. 2008
  12. ncbi Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care
    Denis Poddubnyy
    Department of Rheumatology, Charite Campus Benjamin Franklin, Berlin, Germany
    J Rheumatol 38:2452-60. 2011
    ..To evaluate 2 referral strategies for axial spondyloarthritis (SpA) in patients with chronic low back pain at the primary care level...
  13. ncbi Developments in the scientific and clinical understanding of the spondyloarthritides
    Joachim Sieper
    Department of Rheumatology, Campus Benjamin Franklin, Charite, Hindenburgdamm 30, 12200 Berlin, Germany
    Arthritis Res Ther 11:208. 2009
    ..Only when the exact pathogenesis is clarified will a curative treatment be possible...
  14. ncbi Early referral recommendations for ankylosing spondylitis (including pre-radiographic and radiographic forms) in primary care
    J Sieper
    Medical Department I, Rheumatology, Charite, University Medicine Berlin, Germany
    Ann Rheum Dis 64:659-63. 2005
    ..Primary care physicians need easy to apply parameters to help them identify patients with suspected AS for onward referral. The best measures found were inflammatory back pain and HLA-B27 positivity...
  15. ncbi Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study
    J Sieper
    Benjamin Franklin University Berlin, Berlin, Germany
    Ann Rheum Dis 67:323-9. 2008
    ..To demonstrate the non-inferiority of celecoxib compared with diclofenac in subjects with ankylosing spondylitis (AS)...
  16. ncbi Disease mechanisms in reactive arthritis
    Joachim Sieper
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Curr Rheumatol Rep 6:110-6. 2004
    ..The exact role of such peptides for the pathogenesis of ReA and other spondyloarthritides still has to be defined...
  17. ncbi Early diagnosis of spondyloarthritis
    Jurgen Braun
    Ruhr University, Bochum, Germany
    Nat Clin Pract Rheumatol 2:536-45. 2006
    ..In addition, because of the high incidence of back pain in affected individuals, the development of practical screening parameters that facilitate referral to the rheumatologist is important...
  18. ncbi Can structural damage be prevented in ankylosing spondylitis?
    Joachim Sieper
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, Berlin, Germany
    Curr Opin Rheumatol 21:335-9. 2009
    ..However, it is less clear whether and how structural damage, determined mainly by new bone formation, can be prevented. Recent progress of the research addressing this question is presented here...
  19. ncbi The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis
    J Sieper
    Rheumatology, Medizinische Klinik I, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 68:ii1-44. 2009
    ..The focus of this handbook is on practicality, with many examples of MRI and x ray images, which will help to standardise not only patient care but also the design of clinical studies...
  20. ncbi Concepts and epidemiology of spondyloarthritis
    Joachim Sieper
    Department of Medicine, Rheumatology, Charite, University Medicine Berlin, Germany
    Best Pract Res Clin Rheumatol 20:401-17. 2006
    ..Incidence rates of 0.5-8.2/100 000 population and prevalence rates of 0.2-1.2% have been described for AS, and about double these figures have been reported for SpA...
  21. ncbi Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials
    J Sieper
    Universitatsmedizin Berlin, Campus Benjamin Franklin, Med Klinik I Rheumatologie, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 69:226-9. 2010
    ..To assess uveitis (including iritis and iridocyclitis) incidence from clinical trials of etanercept in patients with ankylosing spondylitis (AS)...
  22. ncbi Adalimumab for the treatment of ankylosing spondylitis
    Joachim Sieper
    Campus Benjamin Franklin, Rheumatology, Medical Department I, Charite, Hindenburgdamm 30, 12200 Berlin, Germany
    Expert Opin Pharmacother 8:831-8. 2007
    ..In open and placebo-controlled trials, the drug was shown to be safe and effective in ankylosing spondylitis patients. Long-term treatment data of up to 2 years are now available, confirming efficacy and acceptable safety...
  23. ncbi Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48
    I H Song
    Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 70:1257-63. 2011
    ....
  24. ncbi Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept
    J Zou
    Rheumatology, Benjamin Franklin Klinikum, Deutsches Rheumaforschungszentrum, Berlin, Germany
    Ann Rheum Dis 62:561-4. 2003
    ..CONCLUSIONS: Neutralisation of peripheral TNFalpha does not induce a down regulation of the ability of T cells to produce TNFalpha but rather an up regulation, possibly due to a counterregulatory mechanism...
  25. ncbi Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years
    J Braun
    Rheumatology Medical Center, Ruhrgebeit, Herne, Ruhr University, Bochum, Germany
    Rheumatology (Oxford) 44:670-6. 2005
    ..This report provides analyses from a 3-yr extension study, as a follow-up to both the 1- and 2-yr open label extensions of the original 3-month randomized controlled trial of infliximab in patients with AS...
  26. ncbi Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept
    M Rudwaleit
    Rheumatology, , Berlin, Germany
    Ann Rheum Dis 64:1305-10. 2005
    ..The potential role of etanercept on deceleration of chronic spinal changes needs further study...
  27. ncbi Analysis of the CD8+ T cell response to the G1 domain of aggrecan in ankylosing spondylitis
    J Zou
    Department of Gastroenterology and Rheumatology, , Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 64:722-9. 2005
    ..CONCLUSION: A G1 peptide-specific CD8+ T cell response is present in AS but also in patients with RA. It does not seem to be HLA-B27 restricted. Whether such a response has a role in the pathogenesis of AS needs clarification...
  28. ncbi Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis
    M Rudwaleit
    Rheumatology, Department of Medicine, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 63:665-70. 2004
    ..TNFalpha blockers have been shown to be highly efficacious in patients with active ankylosing spondylitis (AS)...
  29. ncbi Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial
    J Braun
    Benjamin Franklin Hospital, Free University, Berlin, Germany
    Arthritis Rheum 48:2224-33. 2003
    ..The purpose of this study was to evaluate the efficacy and safety of infliximab treatment of AS for a 1-year period...
  30. ncbi [Adaption and validation of the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for use in Germany]
    J Brandt
    Klinikum Benjamin Franklin, Medizinische Klinik I, Rheumatologie, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 62:264-73. 2003
    ..The purpose of this study was the validation of a German translation of the Bath Ankylosing Spondylitis Index (BASDAI)...
  31. ncbi Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis
    J Brandt
    Benjamin Franklin Hospital, Free University Berlin, Berlin, Germany
    Arthritis Rheum 48:1667-75. 2003
    ..Thus, it seems probable that etanercept must be administered continuously in most AS patients to achieve permanent inhibition of the inflammatory process...
  32. ncbi New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)
    J Sieper
    Medizinische Klinik I, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:784-8. 2009
    ..In the present report, a new approach for the development of IBP classification criteria is discussed...
  33. ncbi The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal
    M Rudwaleit
    Med Klinik I, Charite, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:770-6. 2009
    ..The objective of this study was to develop candidate classification criteria for axial SpA that include patients with but also without radiographic sacroiliitis...
  34. ncbi [Spondylarthritides]
    J Braun
    Abteilung für Gastroenterologie und Rheumatologie, Charite Universitatsmedizin Berlin, Campus Benjamin Franklin, Berlin
    Z Rheumatol 65:613-31; quiz 632. 2006
    ..Patients with persistently active disease benefit from therapy with anti-TNF agents. Physiotherapy is of major importance in the general approach to patients with SpA, especially with AS...
  35. ncbi Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial
    I H Song
    Campus Benjamin Franklin, Med Clinic I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 70:590-6. 2011
    ..To evaluate the potential of etanercept versus sulfasalazine to reduce active inflammatory lesions on whole-body MRI in active axial spondyloarthritis with a symptom duration of less than 5 years...
  36. ncbi Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data
    X Baraliakos
    Rheumazentrum Ruhrgebiet, Herne, Ruhr-University Bochum, Bochum, Germany
    Arthritis Rheum 53:856-63. 2005
    ..Spinal inflammation as depicted by MRI decreased significantly, but a few patients still had some spinal inflammation even after long-term anti-TNF therapy...
  37. ncbi The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection
    M Rudwaleit
    Med Klinik I, Charite, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:777-83. 2009
    ..To validate and refine two sets of candidate criteria for the classification/diagnosis of axial spondyloarthritis (SpA)...
  38. ncbi MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis
    M Rudwaleit
    Medizinische Klinik I, Campus Benjamin Franklin, Charite Medical School Berlin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 67:1276-81. 2008
    ..To evaluate the role of MRI in predicting a Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) improvement of at least 50% (BASDAI 50) upon anti-tumour necrosis factor (TNF) therapy of active ankylosing spondylitis (AS)...
  39. ncbi Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab
    J Sieper
    Department of Rheumatology, , Campus Benjamin Franklin, Berlin, Germany
    Rheumatology (Oxford) 44:1525-30. 2005
    ..Disease activity parameters did not directly correlate with MRI, but both pointed in the same direction. Both types of information may be useful for the definition of response to anti-TNF therapy...
  40. ncbi Multicenter open-label study with infliximab in active ankylosing spondylitis over 28 weeks in daily practice
    H Haibel
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin Hospital, Berlin, Germany
    Clin Exp Rheumatol 26:247-52. 2008
    ..The aim of this study was to prospectively investigate the therapeutic efficacy and safety of infliximab therapy in NSAID-refractory AS patients, with special emphasis on impact on quality of life in daily practice...
  41. ncbi Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial
    I H Song
    Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 62:1290-7. 2010
    ....
  42. ncbi Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis
    J Brandt
    Department of Gastroenterology/Rheumatology, Charit, Medical University Berlin, Campus Benjamin Franklin, Germany
    Rheumatology (Oxford) 44:342-8. 2005
    ..CONCLUSIONS: This study shows that treatment with etanercept is efficacious and safe after readministration over 1 yr in patients with active AS not taking DMARDs or steroids...
  43. ncbi New treatment options in ankylosing spondylitis: a role for anti-TNFalpha therapy
    J Sieper
    Medical Department I, Rheumatology, University Hospital Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 60:iii58-61. 2001
    ..Allergy, lupus-like diseases, and tuberculosis are rare side effects which need to be considered. At first glance, the possible benefits of anti-TNFalpha treatment seem to outweigh these shortcomings, including the high cost...
  44. ncbi Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis
    J Listing
    Deutsches Rheuma ForschungsZentrum, Berlin, Germany
    Ann Rheum Dis 63:1670-2. 2004
    ..To analyse the impact of infliximab treatment on the number of hospital inpatient days and days of sick leave in patients with active ankylosing spondylitis (AS)...
  45. ncbi Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group
    M Rudwaleit
    Department of Rheumatology, Charite University Medicine, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:1520-7. 2009
    ..Magnetic resonance imaging (MRI) of sacroiliac joints has evolved as the most relevant imaging modality for diagnosis and classification of early axial spondyloarthritis (SpA) including early ankylosing spondylitis...
  46. ncbi Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis
    J Brandt
    Department of Gastroenterology/Rheumatology, Charit, Berlin, Germany
    Ann Rheum Dis 63:1438-44. 2004
    ..The ASAS 40% improvement criterion has the advantage of setting a high threshold, but only in patient reported outcomes. The choice between these improvement criteria needs to be based on further validation from upcoming trials...
  47. ncbi [Diagnosis and treatment of ankylosing spondylitis (Bechterew disease)]
    M Rudwaleit
    Medizinische Klinik I -- Rheumatologie, , Campus Benjamin Franklin, Berlin
    Dtsch Med Wochenschr 130:1882-6. 2005
  48. ncbi Identification of novel human aggrecan T cell epitopes in HLA-B27 transgenic mice associated with spondyloarthropathy
    Wolfgang Kuon
    Department of Gastroenterology and Rheumatology, Charite Universitatsmedizin, Berlin, Germany
    J Immunol 173:4859-66. 2004
    ..Our data indicate that HLA-B27-restricted epitopes derived from human aggrecan are involved in the induction of inflammation (tenosynovitis), underlining the importance of HLA-B27 in the pathogenesis of SpA...
  49. ncbi No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial
    H Haibel
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 66:419-21. 2007
    ..To examine the potential therapeutic effect of methotrexate 20 mg given weekly as subcutaneous injections to 20 patients with ankylosing spondylitis refractory to non-steroidal antirheumatic drugs...
  50. ncbi Comparison of a high sensitivity and standard C reactive protein measurement in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis
    D A Poddubnyy
    Department of Rheumatology, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12203 Berlin, Germany
    Ann Rheum Dis 69:1338-41. 2010
    ....
  51. ncbi Frequency of triggering bacteria in patients with reactive arthritis and undifferentiated oligoarthritis and the relative importance of the tests used for diagnosis
    C Fendler
    Department of Medicine, Rheumatology, Klinikum Benjamin Franklin, Free University, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 60:337-43. 2001
    ..CONCLUSIONS: Chlamydia trachomatis, yersinia, and salmonella can be identified as the causative pathogen in about 50% of patients with probable or possible ReA if the appropriate tests are used...
  52. ncbi Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations
    I H Song
    Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 68:1701-7. 2009
    ....
  53. ncbi The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general
    M Rudwaleit
    Department of Medicine, Charite University Medicine, Berlin, Germany
    Ann Rheum Dis 70:25-31. 2011
    ..To evaluate new classification criteria for peripheral spondyloarthritis (SpA) in patients with SpA with peripheral manifestations only...
  54. ncbi Ankylosing spondylitis: an overview
    J Sieper
    Department of Gastroenterology and Rheumatology, UKBF, Free University, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 61:iii8-18. 2002
    ..Emerging biological therapies target the inflammatory processes underlying AS, and thus, may favourably alter the disease process, in addition to providing symptom relief...
  55. ncbi [Diagnosis of reactive arthritis]
    H Haibel
    Charite, Universitatsmedizin Berlin, Campus Benjamin Franklin, Abt f Rheumatologie, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 63:211-5. 2004
    ..To assess the clinical value of a test, it is not only necessary to know the specificity and sensitivity of a test but also the assumed likelihood of the disease (pretest probability)...
  56. ncbi The diagnostic value of scintigraphy in assessing sacroiliitis in ankylosing spondylitis: a systematic literature research
    I H Song
    Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 67:1535-40. 2008
    ..The diagnostic value of scintigraphy in detecting sacroiliitis in patients with spondyloarthritis is not clear...
  57. ncbi Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study
    I H Song
    Department of Rheumatology, Charité Medical University, Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 70:1108-10. 2011
    ..To prospectively explore the short-term efficacy and safety of abatacept in patients with ankylosing spondylitis (AS)...
  58. ncbi CD27+ memory and CD27- effector CD8+ T cells are responsible for a decreased production of proinflammatory cytokines in HLA B27-positive subjects
    S Kohler
    Campus Benjamin Franklin, Charite Berlin, Germany
    Clin Exp Rheumatol 23:840-6. 2005
    ..The aim of this study was to identify CD4+ and CD8+ T cell subsets responsible for the observed lower cytokine secretion capacity in HLA B27-positives...
  59. ncbi [Current status of therapeutic approaches in spondyloarthropathies]
    J Sieper
    Med Klinik I Rheumatologie Universitätsklinikum Benjamin Franklin Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 60:458-63. 2001
    ..Allergy, lupus-like diseases and tuberculosis are rare side effects which need to be addressed. At first glance, the possible benefits of anti-TNF therapy seem to outweigh these shortcomings...
  60. ncbi Atopic disorders in ankylosing spondylitis and rheumatoid arthritis
    M Rudwaleit
    Rheumatology, University Hospital Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 61:968-74. 2002
    ..It may further indicate that the cytokine deviation towards an impaired Th1 pattern in AS is less strong than the cytokine deviation towards Th1 in RA, a finding which may affect future therapeutic approaches...
  61. ncbi Six months open label trial of leflunomide in active ankylosing spondylitis
    H Haibel
    Medical Department I, Rheumatology, Charite, Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Ann Rheum Dis 64:124-6. 2005
    ..To examine the potential therapeutic effects of leflunomide in patients with active AS in an open label study...
  62. ncbi [Diagnosis and early diagnosis of ankylosing spondylitis]
    M Rudwaleit
    Medizinische Klinik I, Gastroenterologie Infektiologie Rheumatologie, Charite Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 63:193-202. 2004
    ..An early and reliable diagnosis is relevant to both the patient and the physician since an early diagnosis allows the best therapy to be introduced and consequently maintained...
  63. ncbi Imaging of sacroiliitis
    J Braun
    Department of Nephrology and Endocrinology, UK Benjamin Franklin, Free University, Berlin, Germany
    Clin Rheumatol 19:51-7. 2000
    ....
  64. ncbi Low incidence of reactive arthritis in children following a salmonella outbreak
    M Rudwaleit
    Section of Rheumatology, Department of Medicine, University Hospital Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 60:1055-7. 2001
    ..To assess the incidence of reactive arthritis (ReA) in an outbreak of salmonella infection in a large cohort of children in Germany...
  65. ncbi Immunological basis for the use of TNFalpha-blocking agents in ankylosing spondylitis and immunological changes during treatment
    J X Zou
    Department of Rheumatology, Klinikum Benjamin Franklin, Free University, Berlin, Germany
    Clin Exp Rheumatol 20:S34-7. 2002
    ..While infliximab induced a downregulation of the production of the T-helper 1-cytokines IFNgamma and TNFalpha, etanercept treatment triggered rather an upregulation of these cytokines secreted by T cells after in vitro stimulation...
  66. ncbi A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs
    D Poddubnyy
    Department of Rheumatology, Charite Campus Benjamin Franklin, Berlin, Germany
    Clin Exp Rheumatol 27:S148-51. 2009
    ..Considering younger age of AS patients and lower prevalence of comorbidities, they are probably at lower risk for cardiovascular and gastrointestinal side effects of short- and long-term NSAID therapy in comparison to RA...
  67. ncbi Therapy of ankylosing spondylitis. Part II: biological therapies in the spondyloarthritides
    J Braun
    Rheumazentrum Ruhrgebiet, Herne and University Medicine Berlin, Campus Benjamin Franklin, Berlin, Germany
    Scand J Rheumatol 34:178-90. 2005
    ..However, severe infections, including tuberculosis, have been reported. These can be largely prevented by appropriate screening. The benefits of anti-TNF therapy in AS seem to outweigh these shortcomings...
  68. ncbi Predominant cellular immune response to the cartilage autoantigenic G1 aggrecan in ankylosing spondylitis and rheumatoid arthritis
    J Zou
    Department of Rheumatology, Klinikum Benjamin Franklin, Free University, Berlin, Germany
    Rheumatology (Oxford) 42:846-55. 2003
    ..G1-immunodominant epitopes were identified. The relevance of this finding for the pathogenesis of AS and RA remains to be established...
  69. ncbi Use of methotrexate in patients with ankylosing spondylitis
    H Haibel
    Charite CBF, Rheumatology, Berlin, Germany
    Clin Exp Rheumatol 28:S128-31. 2010
    ..Furthermore, there is no evidence that MTX increases the effects or prevents the side effects of TNF-blockers if given in combination. In this paper the available data of MTX in AS will be discussed...
  70. ncbi Immunohistological analysis of cytokine expression in human osteoarthritic and healthy cartilage
    V Moos
    Deutsches Rheuma Forschungzentrum, Department of Medicine, Klinikum Benjamin Franklin, Free University, Berlin, Germany
    J Rheumatol 26:870-9. 1999
    ..To investigate osteoarthritic cartilage in comparison to normal cartilage in humans for the presence of the most relevant cytokines/growth factors known to be important for degradation and formation of new cartilage...
  71. ncbi Pathogenesis of reactive arthritis
    J Sieper
    Department of Internal Medicine I, Rheumatology, University Hospital Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Curr Rheumatol Rep 3:412-8. 2001
    ..Because antibiotics have failed so far in the treatment of ReA immunomodulatory therapies, based on a better understanding of the pathogenesis, alone or in combination with antibiotics might be an option for the future...
  72. ncbi Infliximab in the treatment of active and severe ankylosing spondylitis
    J Brandt
    Medizinische Klinik und Poliklinik, Rheumatologie, Universitatsklinikum Benjamin Franklin, Berlin, Germany
    Clin Exp Rheumatol 20:S106-10. 2002
    ..This article gives detailed information about current experience with the new treatment options in active and severe AS with anti-TNFalpha therapy...
  73. ncbi Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis
    Henning Christian Brandt
    Rheumatology, Department of Medicine I, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 66:1479-84. 2007
    ..Referral parameters that are easy for doctors in primary care to apply to patients presenting with possible AS could contribute to earlier diagnosis...
  74. ncbi [The off-label-prescription of TNF-alpha blocking agents for spondyloarthropathies in the context of recent statement by a German federal court]
    J Sieper
    Rheumatologie der Medizinischen Klinik I, , Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 61:688-93. 2002
    ....
  75. ncbi [Diagnosis and antibiotic treatment of reactive arthritis]
    J Sieper
    Medizinische Klinik I - Rheumatologie, , Berlin, Germany
    Dtsch Med Wochenschr 127:1893-6. 2002
  76. ncbi Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial
    Hildrun Haibel
    Benjamin Franklin Hospital, Berlin, Germany
    Arthritis Rheum 54:678-81. 2006
  77. ncbi Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab
    Jianxiang Zou
    Benjamin Franklin Klinikum, Deutsches Rheumaforschungszentrum, Berlin, Germany
    Arthritis Rheum 48:780-90. 2003
    ..This is likely to be a relevant mechanism for the clinical efficacy of this therapy...
  78. ncbi Diverse effects of infliximab and etanercept on T lymphocytes
    Joachim Sieper
    Free University of Berlin, Hospital Benjamin Franklin, Department of Rheumatology, Germany
    Semin Arthritis Rheum 34:23-7. 2005
    ....
  79. ncbi Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis
    Heiner Appel
    Charite Berlin, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 60:3257-62. 2009
    ..The contribution of osteocytes in regulating local bone remodeling in arthritis is unknown. The aim of this study was to investigate the role of osteocytes as contributors to bone remodeling in ankylosing spondylitis (AS)...
  80. ncbi The early disease stage in axial spondylarthritis: results from the German Spondyloarthritis Inception Cohort
    Martin Rudwaleit
    Charité Medical University Hospital, Campus Benjamin Franklin, and German Rheumatism Research Centre, Berlin, Germany
    Arthritis Rheum 60:717-27. 2009
    ..Moreover, we sought to identify determinants of the development of radiographic sacroiliitis...
  81. ncbi How to diagnose axial spondyloarthritis early
    M Rudwaleit
    Rheumatology, Department of Medicine I, Charite Campus Benjamin Franklin, Berlin, Germany
    Ann Rheum Dis 63:535-43. 2004
    ..Chronic low back pain (LBP), the leading symptom of ankylosing spondylitis (AS) and undifferentiated axial spondyloarthritis (SpA), precedes the development of radiographic sacroiliitis, sometimes by many years...
  82. ncbi [Immunopathology of ankylosing spondylitis and other spondyloarthritides]
    H Appel
    Abteilung für Gastroenterologie, Infektiologie und Rheumatologie, Charite Universitatsmedizin Berlin, Hindenburgdamm 30, 12200, Berlin, Deutschland
    Z Rheumatol 67:25-31. 2008
    ..The molecular mechanisms which promote the transition from inflammation to new bone formation in patients with ankylosing spondylitis are not well understood...
  83. ncbi [Outcome parameters in ankylosing spondylitis]
    H Haibel
    Z Rheumatol 65:131-4, 136-8. 2006
    ..However, it could also be shown that conventional disease modifying antirheumatic drugs (DMARDs) are not effective in the treatment of the axial forms of SpA...
  84. ncbi [Ankylosing spondylitis--current state of imaging including scoring methods]
    C E Althoff
    Institut fur Radiologie, Charite Universitatsmedizin Berlin, Charite Campus Mitte, Schumannstrasse 20 21, 10117, Berlin, Deutschland
    Z Rheumatol 65:688-99. 2006
    ..This review article presents the imaging modalities used in AS patients, typical findings, and relevant methods of analysis. The most recent developments are discussed...
  85. ncbi Infliximab for the treatment of ankylosing spondylitis
    M Rudwaleit
    Charite Campus Benjamin Franklin, Rheumatology, Department of Medicine I, Hindenburgdamm 30, 12200 Berlin, Germany
    Expert Opin Biol Ther 5:1095-109. 2005
    ..The short-term benefit/risk ratio of infliximab is clearly in favour of the drug, and it is estimated that at present up to 30% of patients with active AS are in need of this kind of effective treatment...
  86. ncbi [Early diagnosis of spondyloarthritis with special attention to the axial forms]
    M Rudwaleit
    Rheumatologie, Medizinische Klinik I, Charite, Universitätsmedizin Berlin Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Z Rheumatol 64:524-30. 2005
    ..New strategies how to make an early diagnosis and how primary care physicians can screen for these patients are discussed...
  87. ncbi Prevalence and molecular diversity of pHS-2 plasmids, marker for arthritogenicity, among clinical Escherichia coli Shigella isolates
    Thomas Adam
    Institut für Mikrobiologie und Hygiene, Medizinische Fakultät der Humboldt Universität, Charite, Dorotheenstr 96, 10117, Berlin, Germany
    Microbes Infect 5:579-92. 2003
    ..The prevalence pattern of the pHS-2 plasmid matches published data on arthritogenic Shigella isolates, providing additional indirect evidence for the potential validity of this plasmid as a marker for arthritogenicity...
  88. ncbi Inflammatory back pain in ankylosing spondylitis: a reassessment of the clinical history for application as classification and diagnostic criteria
    Martin Rudwaleit
    Charite, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 54:569-78. 2006
    ..In this exploratory study, we sought to evaluate the individual features of IBP and to compose and compare various combinations of features for use as classification and diagnostic criteria...
  89. ncbi The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?
    Martin Rudwaleit
    Charit, Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 52:1000-8. 2005
  90. ncbi The solvent-inaccessible Cys67 residue of HLA-B27 contributes to T cell recognition of HLA-B27/peptide complexes
    Heiner Appel
    Division of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Free University Berlin, Germany
    J Immunol 173:6564-73. 2004
    ..These results demonstrate that a solvent-inaccessible residue in the B pocket of HLA-B27 can affect TCR binding in a peptide-dependent fashion...
  91. ncbi Whole-body magnetic resonance imaging evaluation of widespread inflammatory lesions in a patient with ankylosing spondylitis before and after 1 year of treatment with infliximab
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, , Campus Benjamin Franklin, Berlin, Germany
    J Rheumatol 34:2497-8. 2007
  92. ncbi Immunohistochemical analysis of osteoblasts in zygapophyseal joints of patients with ankylosing spondylitis reveal repair mechanisms similar to osteoarthritis
    Heiner Appel
    Department of Gastroenterology, Infectiology and Rheumatology, Charite Berlin, Campus Benjamin Franklin, Berlin, Germany
    J Rheumatol 37:823-8. 2010
    ..New bone formation of the spine is a typical feature of ankylosing spondylitis (AS). It is unknown whether new bone formation is part of a physiological repair process or a unique pathological entity of the disease...
  93. ncbi A case of axial undifferentiated spondyloarthritis diagnosis and management
    Martin Rudwaleit
    Rheumatology, Department of Medicine I, Charite Universitatsmedizin, Berlin, Germany
    Nat Clin Pract Rheumatol 3:298-303. 2007
    ..A 32-year-old white man presented with features of inflammatory back pain, including awakening at night and morning stiffness. He had acute back pain 4 years earlier as a result of a herniated lumbar disc...
  94. ncbi Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis
    Martin Rudwaleit
    Charite University Medicine Berlin, Campus Benjamin Franklin Hospital, Medical Department I, Rheumatology, Hindenburgdamm 30, 12200 Berlin, Germany
    J Rheumatol 36:801-8. 2009
    ..We evaluated the effectiveness and safety of adalimumab in a large cohort of patients with active ankylosing spondylitis (AS) and identified clinical predictors of good clinical response...
  95. ncbi Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial
    J Braun
    Department of Rheumatology, Benjamin Franklin Hospital, Free University of Berlin, Berlin, Germany
    Lancet 359:1187-93. 2002
    ..BACKGROUND Treatment options for patients with ankylosing spondylitis are few. We aimed to assess the effectiveness of infliximab, an antibody to tumour necrosis factor (TNF)-alpha, in treatment of such patients...
  96. ncbi Bone loss is detected more frequently in patients with ankylosing spondylitis with syndesmophytes
    Kirsten Karberg
    Department of Rheumatology and Gastroenterology, , , Berlin, Germany
    J Rheumatol 32:1290-8. 2005
    ..The finding that more patients with syndesmophytes had reduced bone density than those without suggests that bone growth and bone loss occur in parallel, and the role of inflammation in this process warrants further investigation...
  97. ncbi Identification of HLA-B27-restricted peptides in reactive arthritis and other spondyloarthropathies: computer algorithms and fluorescent activated cell sorting analysis as tools for hunting of HLA-B27-restricted chlamydial and autologous crossreactive pep
    Wolfgang Kuon
    Section of Rheumatology, FU Klinikum Benjamin Franklin, Berlin Hindenburgdamm 30, 12200 Berlin, Germany
    Rheum Dis Clin North Am 29:595-611. 2003
    ....
  98. ncbi Diagnosing early ankylosing spondylitis
    In Ho Song
    Rheumatology, Department of Medicine, Charité Medical University Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany
    Curr Rheumatol Rep 9:367-74. 2007
    ..Finally, referral strategies for patients seen by primary care physicians seem to work well and are currently under further valuation...
  99. ncbi Safety and efficacy of readministration of infliximab after longterm continuous therapy and withdrawal in patients with ankylosing spondylitis
    Xenofon Baraliakos
    Rheumazentrum Ruhrgebiet, Herne Ruhr University, Bochum, Germany
    J Rheumatol 34:510-5. 2007
    ....
  100. ncbi HLA-B27-restricted CD8+ T cell response to cartilage-derived self peptides in ankylosing spondylitis
    Pamir Atagunduz
    , Campus Benjamin Franklin, Berlin, Germany
    Arthritis Rheum 52:892-901. 2005
    ..Future research is necessary to determine whether the identified peptide is of pathogenetic relevance...